Circulating ghrelin levels in patients with inflammatory bowel disease

Peracchi, M.; Bardella, M. T.; Caprioli, F.; Massironi, S.; Conte, D.; Valenti, L.; Ronchi, C.; Beck-Peccoz, P.; Arosio, M.; Piodi, L.
March 2006
Gut;Mar2006, Vol. 55 Issue 3, p432
Academic Journal
The article studies the circulating ghrelin levels in inflammatory bowel disease (IBD) patients. The endocrine and non-endocrine effects of the gut-brain peptide include control of food intake and energy homeostasis. Fasting serum total ghrelin levels, tumor necrosis factor α and C-reactive protein are evaluated in IBD patients and health controls. To measure serum ghrelin, radioimmunnoassay is used.


Related Articles

  • Certolizumab Pegol: In Crohn's Disease.  // BioDrugs;2007, Vol. 21 Issue 3, p195 

    â–´ Certolizumab pegol is a pegylated humanized Fab' fragment of an anti-tumor necrosis factor-a (TNFa) monoclonal antibody, which binds with high affinity to both membrane-bound and soluble TNFa and demonstrates high neutralizing potency for these factors. â–´ The elimination half-life...

  • Etanercept in the Treatment of Active Refractory Crohn's Disease: A Single-Center Pilot Trial. D'Haens, Geert; Swijsen, Caroline; Noman, Maja; Lemmens, Liesbeth; Ceuppens, Jan; Agbahiwe, H.; Geboes, Karel; Rutgeerts, Paul // American Journal of Gastroenterology;Sep2001, Vol. 96 Issue 9, p2564 

    OBJECTIVES: Etanercept, an injectable tumor necrosis factor (TNF) receptor fusion protein, binds and inactivates human TNF and is used in active rheumatoid arthritis. Blocking TNF with monoclonal antibodies has also been beneficial in Crohn's disease. We attempted to determine the efficacy and...

  • Relationship between the tumor necrosis factor alpha polymorphism and the serum C-reactive protein levels in inflammatory bowel disease. Vatay, Ágnes; Bene, Lászlá; Kovács, Ágota; Prohászka, Zoltán; Szalai, Csaba; Romics, László; Fekete, Béla; Karádi, István; Füst, George // Immunogenetics;Jul2003, Vol. 55 Issue 4, p247 

    Inflammatory bowel disease (IBD) is a chronic inflammatory disease of the gastrointestinal tract, including ulcerative colitis (UC) and Crohn's disease (CD). The aim of the study was to determine the prevalence of the tumor necrosis factor alpha (TNF-α) promoter polymorphisms at positions...

  • Certolizumab Pegol for the Treatment of Crohn's Disease. Sandborn, William J.; Feagan, Brian G.; Stoinov, Simeon; Honiball, Pieter J.; Rutgeerts, Paul; Mason, David; Bloomfield, Ralph; Schreiber, Stefan // New England Journal of Medicine;7/19/2007, Vol. 357 Issue 3, p228 

    Background: Certolizumab pegol is a pegylated humanized Fab' fragment that binds tumor necrosis factor a. Methods: In a randomized, double-blind, placebo-controlled trial, we evaluated the efficacy of certolizumab pegol in 662 adults with moderate-to-severe Crohn's disease. Patients were...

  • HVEM Signalling Promotes Colitis. Schaer, Corinne; Hiltbrunner, Stefanie; Ernst, Bettina; Mueller, Christoph; Kurrer, Michael; Kopf, Manfred; Harris, Nicola L. // PLoS ONE;2011, Vol. 6 Issue 4, p1 

    Background: Tumor necrosis factor super family (TNFSF) members regulate important processes involved in cell proliferation, survival and differentiation and are therefore crucial for the balance between homeostasis and inflammatory responses. Several members of the TNFSF are closely associated...

  • Extra-adrenal glucocorticoid synthesis in the intestinal epithelium: more than a drop in the ocean? Noti, Mario; Sidler, Daniel; Brunner, Thomas // Seminars in Immunopathology;Jul2009, Vol. 31 Issue 2, p237 

    Glucocorticoids (GC) are lipophilic hormones commonly used as therapeutics in acute and chronic inflammatory disorders such as inflammatory bowel disease due to their attributed anti-inflammatory and immunosuppressive actions. Although the adrenal glands are the major source of endogenous GC,...

  • A place for TACE. van Deventer, S.J.H. // Gut;Jul2002, Vol. 51 Issue 1, p5 

    Comments on a study by J. Brynskov and colleagues, which examined tumor necrosis factor-alpha converting enzyme (TACE) activity in the colonic mucosa of patients with inflammatory bowel disease. Control of the production and secretion of TNA-alpha at multiple checkpoints; Physiological...

  • Tumour necrosis factor α converting enzyme (TACE) activity in the colonic mucosa of patients with inflammatory bowel disease. Brynskov, J.; Foegh, P.; Pedersen, G.; Ellervik, C.; Kirkegaard, T.; Bingham, A.; Saermark, T. // Gut;Jul2002, Vol. 51 Issue 1, p37 

    Background: Anti-tumour necrosis factor α (TNF-α) antibodies are effective in Crohn's disease and perhaps ulcerative colitis but antigenicity and the high cost have raised interest in other strategies to block TNF-α. These include the TNF-α converting enzyme (TACE) which releases...

  • Lipopolysaccharide modulation of normal enterocyte turnover by toll-like receptors is mediated by endogenously produced tumour necrosis factors α. Ruemmele, F.M.; Beaulieu, J.F.; Dionne, S.; Levy, E.; Seidman, E.G.; Cerf-Bensussan, N.; Lentze, M.J. // Gut;Dec2002, Vol. 51 Issue 6, p842 

    Background: Circulating levels of endotoxin (or lipopolysaccharide (LPS)) and anti-endotoxin antibodies are increased in patients with inflammatory bowel disease, supporting the hypothesis of a role for endogenous bacterial products in the pathogenesis of these disorders. Aim: The aim of this...


Read the Article


Sign out of this library

Other Topics